(Reuters) – Eli Lilly on Thursday reported first-quarter profit above Wall Street estimates, helped by strong sales of its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro.
On an adjusted basis, the U.S. drugmaker earned $3.34 per share for the quarter, compared with analysts’ estimates of $3.02 per share, according to LSEG data.
(Reporting by Bhanvi Satija in Bengaluru and Patrick Wingrove in New York; Editing by Anil D’Silva)
